The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PERIO-02: Phase 1b pressure enabled regional immuno-oncology trial of nelitolimod (SD-101), a class C TLR9 agonist, delivered via hepatic artery infusion +/- checkpoint inhibition in intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
 
Sunyoung S. Lee
No Relationships to Disclose
 
Khaldoun Almhanna
Honoraria - Astellas Pharma; AstraZeneca; Eisai
Consulting or Advisory Role - Daiichi Sankyo
Speakers' Bureau - AstraZeneca; Eisai
 
Rahul Sheth
No Relationships to Disclose
 
Shubham Pant
Consulting or Advisory Role - Alligator Bioscience; AskGene Pharma; AstraZeneca; Boehringer Ingelheim; BPGbio; Ipsen; Janssen; Jazz Pharmaceuticals; Nihon Medi-Physics; Novartis; US WorldMeds; Zymeworks
Research Funding - 4D Pharma (Inst); Amal Therapeutics (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); bionte (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Immuneering (Inst); ImmunoMET (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Purple Biotech (Inst); Rgenix (Inst); Xencor (Inst); Zymeworks (Inst)
 
Joshua Kuban
No Relationships to Disclose
 
Aaron Wilhelm Palmer Maxwell
No Relationships to Disclose
 
Brian Justin Witt
No Relationships to Disclose
 
Jason LaPorte
No Relationships to Disclose
 
Ann-Marie Hulstine
No Relationships to Disclose
 
Bryan Cox
No Relationships to Disclose
 
Richard D. Carvajal
Consulting or Advisory Role - Alkermes; Aura Biosciences; Bristol-Myers Squibb/Celgene; Castle Biosciences; Chimeron Bio; Delcath Systems; Genzyme; Hengrui Pharmaceutical; IDEAYA Biosciences; Immunocore; InxMed; Iovance Biotherapeutics; Merck; Oncosec; Pierre Fabre; PureTech; Regeneron; Rgenix; Sorrento Therapeutics; TriSalus Life Sciences
Speakers' Bureau - Bristol-Myers Squibb/Medarex
Research Funding - Amgen (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
 
Ruth Aroon White
No Relationships to Disclose
 
Joshua Weintraub
No Relationships to Disclose
 
Lindsey Davis
No Relationships to Disclose
 
James Hart
No Relationships to Disclose
 
Robert D. Knight
No Relationships to Disclose
 
Steven C. Katz
No Relationships to Disclose
 
Milind M. Javle
Honoraria - AstraZeneca/MedImmune; EMD Serono/Merck; Incyte; Merck; QED Therapeutics; TransThera Biosciences
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen